| 447.11 -1.01 (-0.23%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 529.73 |
1-year : | 618.73 |
| Resists | First : | 453.54 |
Second : | 529.73 |
| Pivot price | 426.46 |
|||
| Supports | First : | 414.27 |
Second : | 390.01 |
| MAs | MA(5) : | 437.02 |
MA(20) : | 425.86 |
| MA(100) : | 486.95  |
MA(250) : | 480.87 |
|
| MACD | MACD : | -4.1 |
Signal : | -9.2 |
| %K %D | K(14,3) : | 81 |
D(3) : | 75.6 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 628.91 | Low : | 291.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MEDP ] has closed It is unclear right now based on current values. 58.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 454.12 - 456.32 | 456.32 - 458.5 |
| Low: | 435.42 - 438.19 | 438.19 - 440.91 |
| Close: | 441.95 - 446.37 | 446.37 - 450.72 |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Fri, 29 May 2026
MEDPACE HOLDINGS, INC. - COMMON STOCK - David Taylor Congressional Trade on May. 15, 2026 - Quiver Quantitative
Fri, 29 May 2026
The Gross Law Firm Reminds Medpace Holdings, Inc. Investors - GlobeNewswire
Thu, 28 May 2026
[144] Medpace Holdings, Inc. SEC Filing - Stock Titan
Thu, 28 May 2026
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Thu, 28 May 2026
Medpace Stock Is Down 32% From Its 52-Week High: A 2026 Valuation Outlook - TIKR.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 29 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 19.4 (%) |
| Held by Institutions | 88.5 (%) |
| Shares Short | 1,550 (K) |
| Shares Short P.Month | 1,220 (K) |
| EPS | 15.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.95 |
| Profit Margin | 17.1 % |
| Operating Margin | 20 % |
| Return on Assets (ttm) | 17.4 % |
| Return on Equity (ttm) | 77.2 % |
| Qtrly Rev. Growth | 26.5 % |
| Gross Profit (p.s.) | 67.57 |
| Sales Per Share | 93.83 |
| EBITDA (p.s.) | 20.69 |
| Qtrly Earnings Growth | 16.6 % |
| Operating Cash Flow | 739 (M) |
| Levered Free Cash Flow | 491 (M) |
| PE Ratio | 28.12 |
| PEG Ratio | 2.5 |
| Price to Book value | 21.34 |
| Price to Sales | 4.76 |
| Price to Cash Flow | 17.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|